Selenium (Se)-containing peptides may be a valuable bioactive compound to promote gut microbiota-targeted therapeutic methods for intestinal disease and hepatopathy. However, limited information is available on the utilization of selenopeptides by gut microbiota, especially Se’s function. For this purpose, the present study aimed to investigate the protective effect of selenopeptide (RYNA(Se)MNDYT, Se-P2, purity of ≥95%) and its original peptide (RYNAMNDYT, P2, purity of ≥95%) in vivo by the microbiota-metabolite axis and further analyze the potential contribution of Se biofortification to Se-P2 bioactivity. The results showed that Se-P2 exhibits a higher protective effect on lipopolysaccharide (LPS)-induced inflammation than P2, including pathology of the colon and liver, which suggested that the bioactivity of P2 was promoted by the organic combination of Se. Notably, gut microbiota composition tended to be a healthy structure by Se-P2 pretreatment in LPS-injured mice, which had a positive effect on LPS-induced gut microbiota dysbacteriosis. Additionally, only Se-P2 promoted an increase in the relative abundance of Lactobacillus, Alistipes, and Roseburia and a decrease in the relative abundance of Akkermansia, Erysipelatoclostridium, and Bacteroides in LPS-injured mice. The changes in gut microbiota were obviously correlated with the changes in metabolites and affected the metabolic pathways of valine, leucine, isoleucine, phenylalanine, tyrosine, and tryptophan biosynthesis and phenylalanine metabolism. This may be one of the key reasons for Se-P2 to exert bioactivity through the microbiota-metabolite axis. Furthermore, Se-biofortification in selenium-enriched Cordyceps militaris affected the parental proteins of Se-P2 to modulate mitogen-activated protein kinase, GPI anchored protein, and carbohydrate metabolism, translation, folding, sorting and degradation, which may contribute to the bioactivity of Se-P2. Our study provides information on the effect of Se on selenopeptides in vivo, which further promotes the prospective applications of selenopeptides as dietary supplements.

The worldwide distribution of Staphylococcus aureus across food types is an important food safety concern. This study aimed to estimate the prevalence of S. aureus in food products and its relationship with the occurrence and development of diabetes mellitus. A total of 55 articles were included. The pooled prevalence of S. aureus was 30.2%. The highest prevalence of S. aureus was observed in cereals, followed by meat and bean products, and the lowest in confectionery, egg products, and vegetables. The prevalence in dairy and seafood products was similar. Combinations of culture and molecular methods have been used for S. aureus detection. Furthermore, the prevalence of S. aureus in developed countries (Europe and North America) was higher than that in developing countries (Asia and Africa). In addition, the prevalence was higher in the provinces of Xinjiang and Shaanxi than that in Sichuan and Shandong in China, which may be due to the difference in climate and dietary habits. The results revealed that food type, bacterial detection methods, and location can influence the prevalence of S. aureus contamination. Resistance rates to preferred antibiotics against S. aureus were the highest for cephradine, polymyxin B, and penicillin at 82.9%, 82.0%, and 81.3%, respectively. In addition, 17 studies were system reviewed that the S. aureus infections are closely associated with the development of diabetes, and the treatment of probiotic, prebiotic, FMT, and bacteriophage can prevent and control S. aureus infections. This review emphasizes the high prevalence of S. aureus contamination in food, suggesting a potential diabetic infection risk and importance of observing principles of food safety and hygiene to reduce S. aureus.